Brentuximab vedotin (Adcetris)
Brentuximab vedotin combines an antibody to the CD30 protein with a drug called monomethyl auristatin E (MMAE). The antibody delivers MMAE to the lymphoma cells reducing its effect on normal cells.
Brentuximab vedotin is given as an intravenous infusion over 30 minutes. The infusion is usually repeated every 3 weeks and may be given for up to 1 year.
Brentuximab vedotin is currently PBS approved for T cell lymphoma and is being considered for Classical Hodgkin lymphoma at the next PBAC meeting.